Czechia· CZ-0232954

OTOBACID N

A dexamethasone product containing dexamethasone + cinchocaine hydrochloride + butanediol, registered in Czechia by Chiesi Pharmaceuticals GmbH, Vídeň.

ATC S02BA06

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedOTOBACID NATCS02BA06REGISTER NO.CZ-0232954PACKS LISTED1CHECKEDSeptember 28, 2026

The record

At a glance

SÚKL (Czech Republic)
Active substance
DEXAMETHASONE + CINCHOCAINE HYDROCHLORIDE + BUTANEDIOL
Manufacturer
Chiesi Pharmaceuticals GmbH, Vídeň
Country
Czechia (CZ)
ATC code
S02BA06
ATC class
Dexamethasone
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0232954
    1X5ML
    CZK 147.41

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/96eab5a6-0896-467d-ba7c-5639248808c0
GET /v1/drugs/96eab5a6-0896-467d-ba7c-5639248808c0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "AUR GTT SOL",
  "source": "sukl",
  "strength": "0,2MG/G+5MG/G+479,8MG/G",
  "pack_size": "1X5ML",
  "substance": "DEXAMETHASONE + CINCHOCAINE HYDROCHLORIDE + BUTANEDIOL",
  "cz_kod_sukl": "0232954",
  "product_type": "CH",
  "substance_codes": "451,354,9913",
  "registration_state": "R",
  "registration_number": "69/314/97-C"
}

See everything about dexamethasone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.